Haleon Repurchases Nearly 11 Million Shares Under Ongoing Buyback Programme
The UK consumer health giant acquired 10.99 million shares for cancellation across four trading days in mid-August as part of its shareholder return initiative.
Share Repurchase Details
Haleon plc announced the purchase of 10,995,213 ordinary shares for cancellation under its share buyback programme, which was originally announced on 12 March 2026 (6-K filing, 2026-08-17). The consumer health company, which markets brands including Sensodyne, Advil, and Centrum, executed the transactions across four trading days between 10 August and 14 August 2026.
The purchases were conducted across multiple venues including the London Stock Exchange and three CBOE platforms. On 11 August, the company paid between 363.6000 pence and 367.0000 pence per share, with volume-weighted average prices ranging from 365.2253 pence to 365.6591 pence depending on the venue (6-K filing, 2026-08-17).
Prices declined through the subsequent sessions. By 13 August, the trading range had fallen to 355.8000 pence to 360.0000 pence, with volume-weighted averages around 357.95 pence across the different exchanges (6-K filing, 2026-08-17). The filing notes that no purchases were executed on 10 August or 14 August.
Updated Share Capital Structure
Following settlement of these transactions, Haleon's registered share capital stands at 8,809,911,209 ordinary shares of £0.01 each, of which 11,807,443 are held as treasury shares (6-K filing, 2026-08-17). This brings the total number of ordinary shares with voting rights to 8,798,103,766, a figure the company highlighted as relevant for shareholders determining notification requirements under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
The buyback activity represents Haleon's continued commitment to returning capital to shareholders. According to MarginX data, this disclosure follows recent buyback transactions of 12,212,243 shares and 5,246,028 shares in previous reporting periods, indicating sustained repurchase activity throughout the programme's duration.
Market Context
Haleon, which separated from GSK in 2022 to become an independent consumer health company, maintains a market capitalisation of approximately $42 billion. The company's shares closed at $3.577 on its most recent trading session prior to this filing.
The consumer health firm describes itself as "solely focused on better everyday health" with a portfolio spanning six major categories: Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health (6-K filing, 2026-08-17). The company states that its brands are trusted by more than one billion consumers globally.
Upcoming Milestones
Investors will receive further insight into Haleon's operational performance when the company reports its Q3 2026 results, expected on 30 October 2026, according to MarginX data. The earnings release will follow the Federal Reserve's September and October policy meetings, which could influence broader market sentiment toward consumer-focused equities.
The company has made detailed transaction data available through the London Stock Exchange regulatory news service and its investor relations website, in accordance with UK Market Abuse Regulation requirements (6-K filing, 2026-08-17).
This article was generated by MarginX from the 6-K filing on 2026-08-17. It is not investment advice.